Lead Product(s) : VLA1601
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Details : VLA1601 is a highly purified inactivated zika virus vaccine candidate adsorbed on alum, which is being evaluated for the treatment of zika virus infection.
Product Name : VLA1601
Product Type : Vaccine
Upfront Cash : Inapplicable
March 26, 2024
Lead Product(s) : VLA1601
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
